PRCT's EBITDA Miss Triggers Investigation, Testing Reset Narrative's Viability

What happened

PROCEPT BioRobotics reported a $50.2 million adjusted EBITDA loss, far exceeding the $35 million loss management had projected, leading to a 15% stock drop and a law firm investigation into investor losses. The DeepValue master report frames PRCT in a 'WAIT' phase, with its thesis dependent on hitting 2026 procedure targets of 60,000–64,000 and sustaining gross margins above 65% to achieve positive adjusted EBITDA by 4Q26. This earnings discrepancy exposes management's forecasting inaccuracies, challenging the credibility of its recent reset narrative focused on pricing discipline and commercial realignment. Investors now face heightened uncertainty as the miss suggests underlying operational weaknesses, potentially delaying the path to profitability. The event underscores the critical need for PRCT to deliver transparent, sequential progress in procedures and margins to rebuild trust.

Implication

The EBITDA shortfall forces a reassessment of PRCT's near-term prospects, with implications including potential further stock declines if management fails to validate procedure growth and margin targets in the next 90 days. It highlights covenant risks, as cash burn from such losses could approach the $100 million trigger described in filings, raising dilution concerns. Investors must prioritize evidence over messaging, demanding clear KPIs on handpiece-per-procedure normalization and installed-base productivity in future reports. This development reinforces the master report's thesis breakers, such as gross margin stagnation or procedure misses, which could accelerate downside toward the bear case value of $18. Ultimately, patience is warranted only if PRCT demonstrates concrete operational improvements, making the 'WAIT' rating more precarious.

Thesis delta

The news shifts the thesis by materializing execution risks highlighted in the master report, indicating that management's projections are unreliable and increasing skepticism toward the reset narrative. It underscores a need for more conservative assumptions, as the EBITDA miss suggests PRCT may struggle to meet its 2026 targets, potentially delaying profitability milestones. This delta amplifies the urgency for investors to monitor upcoming disclosures for validation or further deterioration.